Insulin-like growth factor-II regulates the expression of vascular endothelial growth factor by the human keratinocyte cell line HaCaT.

Psoriasis is a chronic, relapsing skin disease characterized by enhanced angiogenesis. The pathogenetic process resulting in hypervascularity remains to be further investigated. It has been reported that a potent angiogenic factor, vascular endothelial growth factor (VEGF) is overexpressed in psoriatic epidermis and that the level of insulin-like growth factor II (IGF-II) is significantly elevated in the tissue fluid and serum of the psoriatic lesion. We considered the possibility that IGF-II might function as a paracrine inducer of VEGF. Here, we demonstrated that exposure of HaCaT keratinocytes to IGF-II induced both mRNA and protein expression of VEGF through the MAP kinase (extracellular signal-regulated kinase (ERK2) pathway. Particularly, we determined that phosphorylation of ERK2 but not p38 and JNK1/2 was activated by IGF-II in a time-dependent manner. Additionally, we found that IGF-II treatment induced the expression of MDM2 through the MAP kinase pathway. Moreover, the increase of MDM2 resulted in decreased levels of p53 followed by increased expression of HIF-1alpha and VEGF. Taken together, these results suggest that IGF-II enhances the expression of VEGF in HaCaT cells by increasing HIF-1alpha levels.

[1]  R. Kaufmann,et al.  Increased Sp1 phosphorylation as a mechanism of hepatocyte growth factor (HGF/SF)-induced vascular endothelial growth factor (VEGF/VPF) transcription , 2003, Journal of Cell Science.

[2]  L. Ellis,et al.  Insulin-like Growth Factor 1 Induces Hypoxia-inducible Factor 1-mediated Vascular Endothelial Growth Factor Expression, Which is Dependent on MAP Kinase and Phosphatidylinositol 3-Kinase Signaling in Colon Cancer Cells* , 2002, The Journal of Biological Chemistry.

[3]  D. Schmitt,et al.  IL‐4 and interferon‐γ differentially modulate vascular endothelial growth factor release from normal human keratinocytes and fibroblasts , 2002, Experimental dermatology.

[4]  E. Yazlovitskaya,et al.  Effect of Extracellular Signal-regulated Kinase on p53 Accumulation in Response to Cisplatin* , 2000, The Journal of Biological Chemistry.

[5]  F. McCormick,et al.  Opposing Effects of Ras on p53 Transcriptional Activation of mdm2 and Induction of p19ARF , 2000, Cell.

[6]  J. Araya,et al.  Bradykinin stimulates IL-6 and IL-8 production by human lung fibroblasts through ERK- and p38 MAPK-dependent mechanisms. , 2000, The European respiratory journal.

[7]  P. White,et al.  Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides , 2000, Nature Biotechnology.

[8]  B. Fenton,et al.  Alteration of tumour response to radiation by interleukin-2 gene transfer , 2000, British Journal of Cancer.

[9]  G. Semenza,et al.  Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.

[10]  K. W. Kim,et al.  Identification of angiogenic properties of insulin-like growth factor II in in vitro angiogenesis models , 2000, British Journal of Cancer.

[11]  M. Mildner,et al.  UVA and UVB Radiation Differentially Regulate Vascular Endothelial Growth Factor Expression in Keratinocyte‐derived Cell Lines and in Human Keratinocytes , 1999, Photochemistry and photobiology.

[12]  G. Semenza,et al.  Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. , 1999, Cancer research.

[13]  T. Nakamura,et al.  Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[14]  Yuichi Makino,et al.  Regulation of the Hypoxia-inducible Transcription Factor 1α by the Ubiquitin-Proteasome Pathway* , 1999, The Journal of Biological Chemistry.

[15]  Z. Dong,et al.  Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation , 1998, Oncogene.

[16]  R. Kaufmann,et al.  Hepatocyte growth factor/scatter factor (HGF/SF) induces vascular permeability factor (VPF/VEGF) expression by cultured keratinocytes. , 1998, The Journal of investigative dermatology.

[17]  M. Mildner,et al.  Retinoids Downregulate Vascular Endothelial Growth Factor/Vascular Permeability Factor Production by Normal Human Keratinocytes , 1998 .

[18]  H. Niiro,et al.  MAP kinase pathways as a route for regulatory mechanisms of IL-10 and IL-4 which inhibit COX-2 expression in human monocytes. , 1998, Biochemical and biophysical research communications.

[19]  L. Huang,et al.  Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway , 1998 .

[20]  T. Fojo,et al.  p53 Inhibits Hypoxia-inducible Factor-stimulated Transcription* , 1998, The Journal of Biological Chemistry.

[21]  K. W. Kim,et al.  Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. , 1998, Cancer research.

[22]  D. Creamer,et al.  Overexpression of the angiogenic factor platelet‐derived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis , 1997, The British journal of dermatology.

[23]  J. Caro,et al.  Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. , 1997, The Journal of biological chemistry.

[24]  D. Leroith,et al.  Insulin-like Growth Factor-I Rapidly Activates Multiple Signal Transduction Pathways in Cultured Rat Cardiac Myocytes* , 1997, The Journal of Biological Chemistry.

[25]  P. Agostinis,et al.  Differential stimulation of ERK and JNK activities by ultraviolet B irradiation and epidermal growth factor in human keratinocytes. , 1997, The Journal of investigative dermatology.

[26]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[27]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[28]  H. Dvorak,et al.  Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin. , 1997, The Journal of investigative dermatology.

[29]  C. Ballaun,et al.  Vascular endothelial growth factor production in normal epidermis and in benign and malignant epithelial skin tumors. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[30]  M. Karin,et al.  Mitogen-activated protein kinase cascades and regulation of gene expression. , 1996, Current opinion in immunology.

[31]  H. Auer,et al.  Antioncogene P53 and mitogenic cytokine interleukin-8 aberrantly expressed in psoriatic skin are inversely regulated by the antipsoriatic drug tacrolimus (FK506). , 1996, Biochemical pharmacology.

[32]  C. Stewart,et al.  Insulin-like Growth Factor-II Is an Autocrine Survival Factor for Differentiating Myoblasts (*) , 1996, The Journal of Biological Chemistry.

[33]  A. Gottlieb,et al.  The insulin-like growth factor 1 receptor is expressed by epithelial cells with proliferative potential in human epidermis and skin appendages: correlation of increased expression with epidermal hyperplasia. , 1996, The Journal of investigative dermatology.

[34]  Philip R. Cohen,et al.  PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo(*) , 1995, The Journal of Biological Chemistry.

[35]  H. Dvorak,et al.  Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. , 1995, The Journal of investigative dermatology.

[36]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[37]  H. Dvorak,et al.  Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis , 1994, The Journal of experimental medicine.

[38]  G. Semenza,et al.  A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation , 1992, Molecular and cellular biology.

[39]  H. Dvorak,et al.  Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing , 1992, The Journal of experimental medicine.

[40]  A. Gottlieb,et al.  The insulin-like growth factor I receptor is overexpressed in psoriatic epidermis, but is differentially regulated from the epidermal growth factor receptor , 1992, The Journal of experimental medicine.

[41]  L. Fry,et al.  The immunology of psoriasis , 1992, The British journal of dermatology.

[42]  V. N. Mordovtsev,et al.  Morphology of skin microvasculature in psoriasis. , 1989, The American Journal of dermatopathology.

[43]  P. Rotwein,et al.  Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. , 1989, Endocrine reviews.

[44]  I. Braverman,et al.  Three-Dimensional Reconstruction of Endothelial Cell Gaps in Psoriatic Vessels and Their Morphologic Identity with Gaps Produced by the Intradermal Injections of Histamine , 1986 .

[45]  G. Weinstein,et al.  Cell kinetic basis for pathophysiology of psoriasis. , 1985, The Journal of investigative dermatology.

[46]  J. Folkman.  Angiogenesis in psoriasis: therapeutic implications. , 1972, The Journal of investigative dermatology.

[47]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. , 1997, EXS.

[48]  J. Holly,et al.  Altered insulin-like growth factor-II (IGF-II) level and IGF-binding protein-3 (IGFBP-3) protease activity in interstitial fluid taken from the skin lesion of psoriasis. , 1996, The Journal of investigative dermatology.

[49]  D. Clemmons,et al.  The insulin-like growth factors. , 1993, Annual review of physiology.

[50]  D. Wilson,et al.  Insulin-like growth factors are mitogenic for human keratinocytes and a squamous cell carcinoma. , 1991, The Journal of investigative dermatology.

[51]  Beranek Jt.  Angiogenesis in psoriasis. , 1990 .

[52]  I. Braverman,et al.  Three-dimensional reconstruction of endothelial cell gaps in psoriatic vessels and their morphologic identity with gaps produced by the intradermal injection of histamine. , 1986, Journal of Investigative Dermatology.